Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: Implications for mitochondrial dysfunction in Parkinson disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 9, 2010, Pages 699-706

  Bisaglia, Marco ^a   Soriano, Maria Eugenia ^a   Arduini, Irene ^a   Mammi, Stefano ^a   Bubacco, Luigi ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Dopamine quinone; Glutathione; Mitochondria; NADH; NMR

Indexed keywords

DOPAMINE; GLUTATHIONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRON TRANSPORT; IN VITRO STUDY; MITOCHONDRION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; ULTRAVIOLET SPECTROSCOPY;

EID: 77954959651     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.06.006     Document Type: Article

References (37)

1. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., Marshall F.J., Ravina B.M., Schifitto G., Siderowf A., Tanner C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
2. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007, 30:244-250.
3. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990, 54:823-827.
4. Hirsch E.C. Does oxidative stress participate in nerve cell death in Parkinson's disease?. Eur Neurol 1993, 33(Suppl 1):52-59.
5. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 1998, 13(Suppl 1):24-34.
6. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann Neurol 1998, 44:S72-S84.
7. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978, 14:633-643.
8. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 1999, 73:1127-1137.
9. Gluck M.R., Zeevalk G.D. Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases. J Neurochem 2004, 91:788-795.
10. Khan F.H., Sen T., Maiti A.K., Jana S., Chatterjee U., Chakrabarti S. Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease. Biochim Biophys Acta 2005, 1741:65-74.
11. Jana S., Maiti A.K., Bagh M.B., Banerjee K., Das A., Roy A., Chakrabarti S. Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: implications in Parkinson's disease. Brain Res 2007, 1139:195-200.
12. Dringen R., Gutterer J.M., Hirrlinger J. Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur J Biochem 2000, 267:4912-4916.
13. Sohal R.S., Weindruch R. Oxidative stress, caloric restriction, and aging. Science 1996, 273:59-63.
14. Kang Y., Viswanath V., Jha N., Qiao X., Mo J.Q., Andersen J.K. Brain gamma-glutamyl cysteine synthetase (GCS) mRNA expression patterns correlate with regional-specific enzyme activities and glutathione levels. J Neurosci Res 1999, 58:436-441.
15. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989, 52:515-520.
16. Jenner P., Dexter D.T., Sian J., Schapira A.H., Marsden C.D. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 1992, 32 Sulp.:S82-S87.
17. Spencer J.P., Jenner P., Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. NeuroReport 1995, 6:1480-1484.
18. Costantini P., Chernyak B.V., Petronilli V., Bernardi P. Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. J Biol Chem 1996, 271:6746-6751.
19. Chernyak B.V., Bernardi P. The mitochondrial permeability transition pore is modulated by oxidative agents through both pyridine nucleotides and glutathione at two separate sites. Eur J Biochem 1996, 238:623-630.
20. Costantini P., Petronilli V., Colonna R., Bernardi P. On the effects of paraquat on isolated mitochondria. Evidence that paraquat causes opening of the cyclosporin A-sensitive permeability transition pore synergistically with nitric oxide. Toxicology 1995, 99:77-88.
21. Beatrice M.C., Stiers D.L., Pfeiffer D.R. The role of glutathione in the retention of Ca2+ by liver mitochondria. J Biol Chem 1984, 259:1279-1287.
22. Bernardi P., Broekemeier K.M., Pfeiffer D.R. Recent progress on regulation of the mitochondrial permeability transition pore; a cyclosporin-sensitive pore in the inner mitochondrial membrane. J Bioenerg Biomembr 1994, 26:509-517.
23. Bisaglia M., Mammi S., Bubacco L. Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 2007, 282:15597-15605.
24. Tse D.C., McCreery R.L., Adams R.N. Potential oxidative pathways of brain catecholamines. J Med Chem 1976, 19:37-40.
25. Nicolis S., Zucchelli M., Monzani E., Casella L. Myoglobin modification by enzyme-generated dopamine reactive species. Chemistry 2008, 14:8661-8673.
26. Yang X., Bi S., Yang L., Zhu Y., Wang X. Multi-NMR and fluorescence spectra study the effects of aluminum(III) on coenzyme NADH in aqueous solutions. Spectrochim Acta A Mol Biomol Spectrosc 2003, 59:2561-2569.
27. Yang X., Bi S., Yang L., Hu J., Liu J., Yang Z. NMR spectra and potentiometry studies of aluminum(III) binding with coenzyme NAD+in acidic aqueous solutions. Anal Sci 2003, 19:815-821.
28. Segura-Aguilar J., Baez S., Widersten M., Welch C.J., Mannervik B. Human class Mu glutathione transferases in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome. J Biol Chem 1997, 272:5727-5731.
29. Parker W.D., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989, 26:719-723.
30. Cohen G., Farooqui R., Kesler N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci U S A 1997, 94:4890-4894.
31. Gluck M., Ehrhart J., Jayatilleke E., Zeevalk G.D. Inhibition of brain mitochondrial respiration by dopamine: involvement of H(2)O(2) and hydroxyl radicals but not glutathione-protein-mixed disulfides. J Neurochem 2002, 82:66-74.
32. Gimenez-Xavier P., Gomez-Santos C., Castano E., Francisco R., Boada J., Unzeta M., Sanz E., Ambrosio S. The decrease of NAD(P)H has a prominent role in dopamine toxicity. Biochim Biophys Acta 2006, 1762:564-574.
33. Diaz-Veliz G., Mora S., Dossi M.T., Gomez P., Arriagada C., Montiel J., Aboitiz F., Segura-Aguilar J. Behavioral effects of aminochrome and dopachrome injected in the rat substantia nigra. Pharmacol Biochem Behav 2002, 73:843-850.
34. Zafar K.S., Siegel D., Ross D. A potential role for cyclized quinones derived from dopamine, DOPA, and 3, 4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol Pharmacol 2006, 70:1079-1086.
35. Zhou Z.D., Lim T.M. Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones. Free Radic Res 2009, 43:417-430.
36. Zhou Z.D., Lim T.M. Roles of glutathione (GSH) in dopamine (DA) oxidation studied by improved tandem HPLC plus ESI-MS. Neurochem Res 2009, 34:316-326.
37. Zoccarato F., Toscano P., Alexandre A. Dopamine-derived dopaminochrome promotes H(2)O(2) release at mitochondrial complex I: stimulation by rotenone control by Ca(2+), and relevance to Parkinson disease. J Biol Chem 2005, 280:15587-15594.